Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diagnostic Imaging | 10 | 2019 | 1174 | 1.250 |
Why?
|
| Positron Emission Tomography Computed Tomography | 9 | 2019 | 881 | 1.190 |
Why?
|
| Fluorodeoxyglucose F18 | 8 | 2018 | 1260 | 1.040 |
Why?
|
| Tomography, X-Ray Computed | 22 | 2019 | 7787 | 0.750 |
Why?
|
| Thoracic Neoplasms | 3 | 2018 | 363 | 0.680 |
Why?
|
| Radiotherapy | 5 | 2015 | 1858 | 0.680 |
Why?
|
| Radiographic Image Enhancement | 2 | 2018 | 411 | 0.620 |
Why?
|
| Positron-Emission Tomography | 10 | 2019 | 2199 | 0.600 |
Why?
|
| Radiopharmaceuticals | 7 | 2018 | 1341 | 0.570 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 238 | 0.530 |
Why?
|
| Lung Neoplasms | 14 | 2019 | 12038 | 0.530 |
Why?
|
| Diagnostic Errors | 2 | 2018 | 517 | 0.520 |
Why?
|
| Multimodal Imaging | 7 | 2019 | 551 | 0.490 |
Why?
|
| Digestive System Diseases | 1 | 2014 | 39 | 0.470 |
Why?
|
| Genital Neoplasms, Female | 3 | 2019 | 794 | 0.460 |
Why?
|
| Urologic Diseases | 1 | 2014 | 84 | 0.450 |
Why?
|
| Antineoplastic Agents | 6 | 2018 | 14638 | 0.430 |
Why?
|
| Solitary Pulmonary Nodule | 4 | 2015 | 125 | 0.420 |
Why?
|
| Vulvar Neoplasms | 2 | 2018 | 235 | 0.410 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2012 | 52 | 0.400 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2019 | 1903 | 0.350 |
Why?
|
| Hydrocephalus | 1 | 2012 | 259 | 0.340 |
Why?
|
| Brain Diseases | 1 | 2012 | 411 | 0.320 |
Why?
|
| Blood Vessels | 3 | 2015 | 232 | 0.300 |
Why?
|
| Radiation Injuries | 2 | 2014 | 1476 | 0.300 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 514 | 0.300 |
Why?
|
| Diagnosis, Differential | 12 | 2019 | 4838 | 0.290 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 617 | 0.280 |
Why?
|
| Thorax | 3 | 2019 | 232 | 0.270 |
Why?
|
| Neoplasms | 7 | 2014 | 15931 | 0.220 |
Why?
|
| Pericardium | 2 | 2015 | 147 | 0.220 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2395 | 0.190 |
Why?
|
| Humans | 46 | 2019 | 270601 | 0.190 |
Why?
|
| Radiography, Thoracic | 3 | 2019 | 477 | 0.180 |
Why?
|
| Artifacts | 3 | 2018 | 537 | 0.170 |
Why?
|
| Neoplasm Staging | 13 | 2019 | 14021 | 0.170 |
Why?
|
| Tomography, Emission-Computed | 2 | 2011 | 334 | 0.160 |
Why?
|
| Leukemia, Lymphoid | 1 | 2019 | 289 | 0.150 |
Why?
|
| Vaginal Neoplasms | 2 | 2018 | 152 | 0.150 |
Why?
|
| Liver Diseases | 2 | 2014 | 599 | 0.150 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2017 | 1270 | 0.150 |
Why?
|
| Bronchial Neoplasms | 1 | 2017 | 82 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2019 | 818 | 0.140 |
Why?
|
| Lung | 6 | 2018 | 3284 | 0.140 |
Why?
|
| Postoperative Complications | 1 | 2012 | 5673 | 0.140 |
Why?
|
| Bevacizumab | 3 | 2018 | 967 | 0.130 |
Why?
|
| Contrast Media | 5 | 2014 | 1505 | 0.130 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 690 | 0.130 |
Why?
|
| Abdomen | 2 | 2014 | 346 | 0.120 |
Why?
|
| Pelvis | 2 | 2014 | 381 | 0.120 |
Why?
|
| Female | 18 | 2019 | 148790 | 0.120 |
Why?
|
| Bone Cements | 1 | 2015 | 50 | 0.120 |
Why?
|
| Pelvic Exenteration | 1 | 2015 | 112 | 0.120 |
Why?
|
| Splenic Diseases | 1 | 2014 | 59 | 0.110 |
Why?
|
| Gonadal Disorders | 1 | 2013 | 8 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 5581 | 0.110 |
Why?
|
| Pleura | 1 | 2015 | 130 | 0.110 |
Why?
|
| Leukemia, Myeloid | 1 | 2019 | 993 | 0.110 |
Why?
|
| Pelvic Neoplasms | 1 | 2015 | 200 | 0.110 |
Why?
|
| Iatrogenic Disease | 1 | 2014 | 194 | 0.110 |
Why?
|
| Task Performance and Analysis | 1 | 2013 | 130 | 0.110 |
Why?
|
| Middle Aged | 13 | 2019 | 90450 | 0.110 |
Why?
|
| Intestinal Diseases | 1 | 2014 | 128 | 0.110 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2015 | 257 | 0.110 |
Why?
|
| Lymphatic Diseases | 1 | 2013 | 128 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 7912 | 0.110 |
Why?
|
| Urogenital System | 1 | 2013 | 60 | 0.100 |
Why?
|
| Pleural Neoplasms | 1 | 2017 | 485 | 0.100 |
Why?
|
| Heart Neoplasms | 1 | 2015 | 209 | 0.100 |
Why?
|
| Pericardial Effusion | 1 | 2013 | 124 | 0.100 |
Why?
|
| Digestive System | 1 | 2013 | 120 | 0.100 |
Why?
|
| Aged | 10 | 2019 | 73534 | 0.100 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2012 | 15 | 0.100 |
Why?
|
| Ileus | 1 | 2012 | 30 | 0.100 |
Why?
|
| Lymphatic Metastasis | 4 | 2017 | 4969 | 0.100 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2012 | 39 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2014 | 234 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 4964 | 0.100 |
Why?
|
| Mediastinum | 1 | 2013 | 276 | 0.100 |
Why?
|
| Dyspnea | 1 | 2015 | 420 | 0.100 |
Why?
|
| Esophagus | 1 | 2015 | 562 | 0.100 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2012 | 109 | 0.090 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 342 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 586 | 0.090 |
Why?
|
| Ovariectomy | 1 | 2012 | 370 | 0.090 |
Why?
|
| Memory | 1 | 2013 | 444 | 0.090 |
Why?
|
| Radiography | 2 | 2012 | 1993 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 380 | 0.090 |
Why?
|
| Ovarian Neoplasms | 2 | 2019 | 4800 | 0.080 |
Why?
|
| Pancreatitis | 1 | 2012 | 294 | 0.080 |
Why?
|
| Gastroenteritis | 1 | 2012 | 350 | 0.080 |
Why?
|
| Fibrosis | 1 | 2012 | 715 | 0.080 |
Why?
|
| Neuroimaging | 1 | 2012 | 402 | 0.080 |
Why?
|
| Heart | 1 | 2015 | 1173 | 0.080 |
Why?
|
| Mesothelioma | 1 | 2013 | 558 | 0.080 |
Why?
|
| Peritoneal Diseases | 1 | 2008 | 34 | 0.080 |
Why?
|
| Inguinal Canal | 1 | 2008 | 64 | 0.080 |
Why?
|
| Male | 11 | 2019 | 128395 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 2394 | 0.070 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2018 | 2458 | 0.070 |
Why?
|
| Neutropenia | 1 | 2012 | 1006 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 6193 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2012 | 718 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2012 | 679 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2014 | 17075 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2012 | 751 | 0.070 |
Why?
|
| Abdominal Neoplasms | 1 | 2008 | 251 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2013 | 1331 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 31084 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 10402 | 0.060 |
Why?
|
| False Positive Reactions | 2 | 2015 | 374 | 0.050 |
Why?
|
| Tuberculosis | 1 | 2010 | 613 | 0.050 |
Why?
|
| Rectal Neoplasms | 1 | 2011 | 1240 | 0.050 |
Why?
|
| Survival Rate | 2 | 2013 | 12527 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2019 | 33811 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 4964 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 5157 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 1825 | 0.050 |
Why?
|
| Lymphoma | 1 | 2010 | 1516 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 3416 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5257 | 0.040 |
Why?
|
| Palliative Care | 1 | 2012 | 2175 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2013 | 3240 | 0.040 |
Why?
|
| Risk Factors | 4 | 2019 | 17855 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2012 | 8602 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 5318 | 0.040 |
Why?
|
| Arginine Vasopressin | 1 | 2018 | 66 | 0.040 |
Why?
|
| Cervix Uteri | 1 | 2019 | 245 | 0.040 |
Why?
|
| Adult | 5 | 2017 | 81960 | 0.030 |
Why?
|
| Radiologists | 1 | 2019 | 180 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 398 | 0.030 |
Why?
|
| Infant | 1 | 2012 | 13992 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 3707 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 7919 | 0.030 |
Why?
|
| Ovary | 1 | 2019 | 686 | 0.030 |
Why?
|
| Enoxaparin | 1 | 2015 | 56 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 4837 | 0.030 |
Why?
|
| Muscle, Striated | 1 | 2013 | 13 | 0.030 |
Why?
|
| Warfarin | 1 | 2015 | 145 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 147 | 0.030 |
Why?
|
| Uterine Neoplasms | 1 | 2018 | 578 | 0.030 |
Why?
|
| Adipose Tissue, Brown | 1 | 2013 | 110 | 0.030 |
Why?
|
| Quinazolines | 1 | 2017 | 956 | 0.030 |
Why?
|
| Mutation | 3 | 2018 | 15905 | 0.020 |
Why?
|
| Observer Variation | 1 | 2013 | 709 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2015 | 520 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2011 | 120 | 0.020 |
Why?
|
| Pyridines | 1 | 2017 | 1313 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 1250 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 4053 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2018 | 2376 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2015 | 777 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2015 | 1581 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 16719 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2018 | 1389 | 0.020 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 1385 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2017 | 1551 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1337 | 0.020 |
Why?
|
| ras Proteins | 1 | 2012 | 804 | 0.020 |
Why?
|
| Genomics | 1 | 2018 | 2832 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 2178 | 0.020 |
Why?
|
| Biopsy | 1 | 2014 | 3491 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 6867 | 0.020 |
Why?
|
| Pregnancy | 1 | 2019 | 7914 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 3395 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2013 | 39922 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 4878 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 1403 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2008 | 360 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2012 | 1336 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 5776 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 2618 | 0.010 |
Why?
|
| Prognosis | 2 | 2011 | 22520 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6257 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 9041 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 9460 | 0.010 |
Why?
|
| Time Factors | 1 | 2012 | 12971 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 32684 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 15270 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 22219 | 0.010 |
Why?
|